Compare WAY & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAY | IOVA |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 968.6M |
| IPO Year | 2024 | N/A |
| Metric | WAY | IOVA |
|---|---|---|
| Price | $32.58 | $2.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $47.29 | $10.36 |
| AVG Volume (30 Days) | 2.3M | ★ 9.8M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $1,039,842,000.00 | $250,425,000.00 |
| Revenue This Year | $16.37 | $60.94 |
| Revenue Next Year | $16.85 | $60.85 |
| P/E Ratio | $52.49 | ★ N/A |
| Revenue Growth | 14.76 | ★ 175.62 |
| 52 Week Low | $29.40 | $1.64 |
| 52 Week High | $48.11 | $8.56 |
| Indicator | WAY | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 46.56 |
| Support Level | $29.40 | $2.18 |
| Resistance Level | $35.64 | $2.32 |
| Average True Range (ATR) | 1.40 | 0.12 |
| MACD | -0.36 | -0.01 |
| Stochastic Oscillator | 39.95 | 18.11 |
Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.